Laboratory of Proteomics and Analytical Technologies

国家癌症研究所(NCI)-弗雷德里克的蛋白质组学和分析技术实验室(LPAT)进行了重组，以向研究界提供更有效的服务。LPAT包括五个专业组：蛋白质鉴定、定量蛋白质组学、代谢组学分析、类固醇激素分析以及分离技术和分析开发。这些小组中的每一个都由LPAT的一名科学家领导，他们在各自的研究领域具有经验和专业知识。在过去的一年里，该实验室在技术开发和应用领域都取得了几项成功。在将代谢组学能力带给NCI进行全球和有针对性的研究方面已经取得了很好的进展。LPAT继续开发和探索在可供分析的样本类型(例如，福尔马林固定的组织)和样本制备方法中改进蛋白质组学分析的方法，以获得更准确的结果(例如，用于磷肽鉴定的稳定同位素标记)。已经商定，400兆赫核磁共振将从LPAT中移除，并放置在约瑟夫·巴奇博士指导下的一个中央核磁共振设施中。LPAT在维护和操作这一仪器方面的作用仍有待确定。

The Laboratory of Proteomics and Analytical Technologies (LPAT) at the National Cancer Institute (NCI) -Frederick has undergone a restructuring to provide more effective service to the research community. LPAT contains five specialty groups: Protein Identification, Quantitative Proteomics, Metabolomic Analysis, Steroid Hormone Analysis, and Separation Technologies and Assay Development. Each of these groups is led by an LPAT scientist with experience and expertise in his or her respective area of research. The laboratory has seen several successes in the past year, in the areas of both technology development and applications. Excellent progress has been made in bringing a metabolomics capability to the NCI for both global and targeted studies. LPAT continues to develop and explore methods for improved proteomic analysis both in the types of samples available for analysis (e.g., formalin-fixed tissue) and in sample preparation methods for more exact results (e.g., stable isotope labeling for phosphopeptide identification). It has been agreed that the 400 MHz NMR will be removed from LPAT and placed within a centralized nuclear magnetic resonance facility under the direction of Dr. Joseph Barchi. LPAT's role in maintaining and operating this instrument is still to be determined.